Safety and Clinical Outcomes of an Equine-Derived Heptavalent Botulinum Antitoxin Treatment for Confirmed or Suspected Botulism in the United States

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

<p class="first" id="d11079928e127">Botulism is a rare, life-threatening paralytic illness. Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine) (BAT) manufactured by Emergent BioSolutions Canada Inc is an equine-derived heptavalent botulinum antitoxin product indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A-G in adults and pediatric patients. BAT product was US-licensed in 2013. </p>

Related collections

Author and article information

Journal

Title: Clinical Infectious Diseases

Publisher: Oxford University Press (OUP)

ISSN (Print): 1058-4838

ISSN (Electronic): 1537-6591

Publication date Created: June 15 2019

Publication date (Electronic): June 15 2019

Affiliations

[1 ]Clinical Research Department, Emergent BioSolutions Canada Incorporated, Winnipeg, Canada

[2 ]Pharmacovigilance Department, Emergent BioSolutions Canada Incorporated, Winnipeg, Canada

[3 ]Biostatistics Department, Emergent BioSolutions Canada Incorporated, Winnipeg, Canada

[4 ]Medical Affairs Department, Emergent BioSolutions Incorporated, Gaithersburg, United States of America

Article

DOI: 10.1093/cid/ciz515

PubMed ID: 31209461

SO-VID: 3707baed-7251-4df4-b47c-31a689606108

License:

https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model

History

Data availability:

Comments

Comment on this article

scite_

Cited by 11

See all cited by

- Version 1